AI Article Synopsis
- Current treatments for pancreatic cancer have limited effectiveness, prompting a study on the combined use of sorafenib and gemcitabine to enhance patient outcomes.
- The research involved experimenting with pancreatic cancer cells to assess how the drugs work together, looking into factors like cell growth, programmed cell death (apoptosis), and specific molecular changes.
- Results showed that the combination of sorafenib and gemcitabine significantly inhibited cell proliferation and increased apoptosis, indicating a stronger therapeutic effect compared to either drug alone.
Article Abstract
Background: Current treatments have a modest impact on survival of pancreatic cancer patients and this study investigates the interaction between sorafenib and gemcitabine and the molecular pharmacodynamics of this combination.
Methods: The pancreatic cancer cells were treated with sorafenib and gemcitabine, alone or in combination. The effects of treatments were evaluated on cell proliferation, cell cycle, apoptosis, phosphorylation of Akt, c-Kit, ERK and VEGFR2, and expression of genes related to drug activity.
Results: Gemcitabine and sorafenib synergistically interacted on the inhibition of cell proliferation, and assessment of apoptosis demonstrated that drug associations increased the apoptotic index. Sorafenib reduced c-Kit, ERK and VEGFR2 activation and on the other hand, gemcitabine inhibited Akt phosphorylation. Moreover, quantitative PCR showed that sorafenib modulated the expression of genes related to gemcitabine activity, while gemcitabine induced the expression of RKIP.
Conclusion: These data demonstrate that gemcitabine and sorafenib combination displays a synergistic effect in pancreatic cancer cells.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000320031 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The landscape in telomere related gene prognostic signature for survival and medication treatment effectiveness prediction in hepatocellular carcinoma.
Discov Oncol
December 2024
Department of Pediatrics, The Affiliated Suqian Hospital of Xuzhou Medical University, Jiangsu, China.
Objective: Telomeres, made of repetitive DNA sequences and shelterin complexes, which were found at the ends of chromosomes and had been extensively studied in cancer research. However, in hepatocellular carcinoma (HCC) was still relatively scarce. In this study, we investigated the correlation between telomerase-related genes (TRGs) and the prognosis and immunotherapy of HCC patients to enhance clinical outcomes.
View Article and Find Full Text PDFIdentification of a Novel Mesenchymal Stem Cell-Related Signature for Predicting the Prognosis and Therapeutic Responses of Bladder Cancer.
Stem Cells Int
November 2024
Institute of Urology, Key Laboratory of Gansu Province for Urological Diseases, Gansu Urological Clinical Center, Lanzhou University Second Hospital, Lanzhou 730030, China.
Article Synopsis
- Mesenchymal stem cells (MSCs) show a specific tendency to move towards tumors, impacting cancer growth, treatment resistance, and immune response, prompting research into MSC-related biomarkers for better predicting bladder cancer outcomes.
- This study used data from TCGA and GSE31684 to identify genes linked to MSCs and created a risk assessment model through advanced statistical analysis techniques.
- The final prognostic model highlighted five key genes and classified bladder cancer patients into risk categories, revealing that high MSC-risk patients faced worse outcomes and lower responsiveness to immunotherapy and specific chemotherapy drugs compared to low MSC-risk patients.
inhibited the growth of primary liver cancer by inducing early apoptosis and senescence, .
Front Microbiol
November 2024
Department of Gastroenterology, Hepatology, Infectious Diseases, and Endocrinology, Hannover Medical School, Hanover, Germany.
Article Synopsis
- Primary liver cancer (PLC), including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), has a high mortality rate and current treatments are limited with severe side effects, highlighting the need for new therapies.
- The study investigates the anticancer effects of two Lactobacilli strains (Lp 12 and Lp 355), derived from grapes, and compares them to the well-studied strain (Lc 393) on PLC cell lines, testing them in various forms and combinations with standard chemotherapy.
- Results indicate that both live suspensions and sonicated extracts of the Lactobacilli strains significantly inhibited PLC cell growth and showed synergistic effects when combined with chemotherapeutics, allowing for lower doses
Multi-omics Insights into PDHA1 as a Predictive Biomarker for Prognosis, Immunotherapy Efficacy, and Drug Sensitivity in Hepatocellular Carcinoma.
ACS Omega
November 2024
Department of Infectious Diseases, Zhoushan Hospital, Wenzhou Medical University, Zhoushan 316021, China.
Article Synopsis
- PDHA1 is linked to changes in metabolism during tumor growth and shows potential as a predictor for drug sensitivity in hepatocellular carcinoma (HCC), although this area hasn't been thoroughly explored yet.
- The study revealed that PDHA1 levels are higher in HCC tissues than in normal tissues and are associated with poorer patient outcomes, as well as with the presence of immune cells.
- It was found that PDHA1 can serve as an independent prognostic factor for HCC, and higher expression is related to increased sensitivity to certain chemotherapy drugs, supported by strong binding in molecular docking tests.
N6-methyladenosine regulators in hepatocellular carcinoma: investigating the precise definition and clinical applications of biomarkers.
Biol Direct
November 2024
Department of Hepatopancreatobiliary Surgery, Hangzhou Institute of Medicine (HIM), Zhejiang Cancer Hospital, Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
Background: Accurately identifying effective biomarkers and translating them into clinical practice have significant implications for improving clinical outcomes in hepatocellular carcinoma (HCC). In this study, our objective is to explore appropriate methods to improve the accuracy of biomarker identification and investigate their clinical value.
Methods: Concentrating on the N6-methyladenosine (m6A) modification regulators, we utilized dozens of multi-omics HCC datasets to analyze the expression patterns and genetic features of m6A regulators.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!